Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study
W. Wolfgang Fleischhacker, Jana Podhorná, Martina Gröschl, et al.
The Lancet Psychiatry (2021) Vol. 8, Iss. 3, pp. 191-201
Closed Access | Times Cited: 101

Showing 26-50 of 101 citing articles:

Towards Enhancing Drug Development Methodology to Treat Cognitive Impairment Associated With Schizophrenia and Other Neuropsychiatric Conditions: Insights From 2 Decades of Clinical Trials
W. P. Horan, Amir H Kalali, Stephen K. Brannan, et al.
Schizophrenia Bulletin (2025)
Open Access | Times Cited: 1
Technology and Mental Health: State of the Art for Assessment and Treatment
Philip D. Harvey, Colin A. Depp, Albert Rizzo, et al.
American Journal of Psychiatry (2022) Vol. 179, Iss. 12, pp. 897-914
Closed Access | Times Cited: 34
Rational and Translational Implications of D-Amino Acids for Treatment-Resistant Schizophrenia: From Neurobiology to the Clinics
Andrea de Bartolomeis, Licia Vellucci, Mark C. Austin, et al.
Biomolecules (2022) Vol. 12, Iss. 7, pp. 909-909
Open Access | Times Cited: 29
Functional crosstalk of the glycine transporter GlyT1 and NMDA receptors
Dolores Piniella, Francisco Zafra
Neuropharmacology (2023) Vol. 232, pp. 109514-109514
Open Access | Times Cited: 19
Novel Compounds in the Treatment of Schizophrenia—A Selective Review
Eva-Maria Tsapakis, Kalliopi Diakaki, Apostolos Miliaras, et al.
Brain Sciences (2023) Vol. 13, Iss. 8, pp. 1193-1193
Open Access | Times Cited: 18
Functional connectivity signatures of NMDAR dysfunction in schizophrenia—integrating findings from imaging genetics and pharmaco-fMRI
Arnim Johannes Gaebler, Nilüfer Fakour, Felix Stöhr, et al.
Translational Psychiatry (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 17
Cognitive Deficit in Schizophrenia: From Etiology to Novel Treatments
Antón L. Martínez, José Brea, Sara Rico, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 18, pp. 9905-9905
Open Access | Times Cited: 33
Metformin improves cognitive impairment in patients with schizophrenia: associated with enhanced functional connectivity of dorsolateral prefrontal cortex
Tiannan Shao, Jing Huang, Yuxin Zhao, et al.
Translational Psychiatry (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 15
A new era for schizophrenia drug development – Lessons for the future
Kiri Granger, Michael Sand, Sheryl Caswell, et al.
Drug Discovery Today (2023) Vol. 28, Iss. 7, pp. 103603-103603
Open Access | Times Cited: 14
Negative Symptoms in Schizophrenia: An Update on Research Assessment and the Current and Upcoming Treatment Landscape
Preetika Govil, Joshua T. Kantrowitz
CNS Drugs (2025)
Closed Access
Novel Treatments for Schizophrenia
Steven M. Paul, Alan Breier
Oxford University Press eBooks (2025), pp. 231-246
Closed Access
Schizophrenia Management: Systematic Review of Current Medications and Phase-3 Agents (2008–2024)
Salma Abdelmoteleb, Jayant Totlani, Salma Ramadan, et al.
Neuroscience Applied (2025) Vol. 4, pp. 105507-105507
Open Access
Novel pharmaceutical treatment approaches for schizophrenia: a systematic literature review
Anan S. Jarab, Walid Al‐Qerem, Adam Khdour, et al.
European Journal of Clinical Pharmacology (2025)
Closed Access
Cognitive impairment in schizophrenia: when, what, and is it remediable?
Ashlee Guzman, Philip D. Harvey
Current Opinion in Psychiatry (2025)
Closed Access
IUPHAR Review - Novel therapeutic targets for schizophrenia treatment: a translational perspective
Veronica Begni, Alessia Marchesin, Marco Andrea Riva
Pharmacological Research (2025), pp. 107690-107690
Open Access
Modulation of the human GlyT1 by clinical drugs and cholesterol
Na Li, Yiqing Wei, Renjie Li, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Directly and Indirectly Targeting the Glycine Modulatory Site to Modulate NMDA Receptor Function to Address Unmet Medical Needs of Patients With Schizophrenia
Ju-Chun Pei, Da-Zhong Luo, Shiang-Shin Gau, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 29
The glutamate/N-methyl-d-aspartate receptor (NMDAR) model of schizophrenia at 35: On the path from syndrome to disease
Daniel C. Javitt, Joshua T. Kantrowitz
Schizophrenia Research (2022) Vol. 242, pp. 56-61
Open Access | Times Cited: 20
Interactions Involving Glycine and Other Amino Acid Neurotransmitters: Focus on Transporter-Mediated Regulation of Release and Glycine–Glutamate Crosstalk
Luca Raiteri
Biomedicines (2024) Vol. 12, Iss. 7, pp. 1518-1518
Open Access | Times Cited: 4
Conceptualization and characterization of “primary” and “secondary” cognitive impairment in schizophrenia
Antonio Vita, Gabriele Nibbio, Sergio Barlati
Psychiatry Research (2024) Vol. 340, pp. 116126-116126
Open Access | Times Cited: 4
Finding the Right Dose: NMDA Receptor–Modulating Treatments for Cognitive and Plasticity Deficits in Schizophrenia and the Role of Pharmacodynamic Target Engagement
Pejman Sehatpour, Joshua T. Kantrowitz
Biological Psychiatry (2024) Vol. 97, Iss. 2, pp. 128-138
Closed Access | Times Cited: 4
Dysfunction of the NMDA Receptor in the Pathophysiology of Schizophrenia and/or the Pathomechanisms of Treatment-Resistant Schizophrenia
Ruri Okubo, Motohiro Okada, Eishi Motomura
Biomolecules (2024) Vol. 14, Iss. 9, pp. 1128-1128
Open Access | Times Cited: 4
The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 Trials
William P. Horan, Colin Sauder, Philip D. Harvey, et al.
American Journal of Psychiatry (2024)
Closed Access | Times Cited: 4
Commentary
Richard S.E. Keefe
Schizophrenia Bulletin (2025)
Open Access
D-Serine: A Cross Species Review of Safety
Amir Mohammad Meftah, Hiroshi Hasegawa, Joshua T. Kantrowitz
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 23

Scroll to top